RPG Life Sciences (NSE:RPGLIFE) PE Ratio without NRI: 35.91 (As of Jul. 07, 2026) — 18% Above Median


NSE:RPGLIFE RPG Life Sciences Ltd NSE:RPGLIFE
92 GF Score
Price ₹2,440.30
GF Value ₹2,353.66
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is RPG Life Sciences PE Ratio without NRI?

RPG Life Sciences NSE:RPGLIFE +0.98% 92 PE Ratio without NRI is 35.91 as of Jul. 07, 2026, which is 18% above its 10-year median of 30.43. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 92/100 and a GF Value™ of ₹2,353.66 (Fairly Valued). The stock has 5 warning signs investors should review. Among 654 Drug Manufacturers companies, RPG Life Sciences ranks worse than 71.71% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-07), RPG Life Sciences's share price is ₹2440.30. RPG Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹67.96. Therefore, RPG Life Sciences's PE Ratio without NRI for today is 35.91.

During the past 13 years, RPG Life Sciences's highest PE Ratio without NRI was 145.85. The lowest was 9.92. And the median was 30.43.

RPG Life Sciences's EPS without NRI for the three months ended in Mar. 2026 was ₹17.59. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹67.96.

As of today (2026-07-07), RPG Life Sciences's share price is ₹2440.30. RPG Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹69.64. Therefore, RPG Life Sciences's PE Ratio (TTM) for today is 35.04.

Warning Sign:

RPG Life Sciences Ltd stock PE Ratio (=34.7) is close to 1-year high of 35.37.

During the past years, RPG Life Sciences's highest PE Ratio (TTM) was 100.87. The lowest was 9.92. And the median was 24.62.

RPG Life Sciences's EPS (Diluted) for the three months ended in Mar. 2026 was ₹18.08. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹69.64.

RPG Life Sciences's EPS (Basic) for the three months ended in Mar. 2026 was ₹18.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹69.64.


RPG Life Sciences  (NSE:RPGLIFE) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


RPG Life Sciences PE Ratio without NRI Related Terms


RPG Life Sciences PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for RPG Life Sciences's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RPG Life Sciences PE Ratio without NRI Chart

RPG Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.20 17.25 30.32 33.73 30.26

RPG Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.73 38.60 33.15 36.56 30.26

NSE:RPGLIFE vs ZTS, UTHR: PE Ratio without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RPG Life Sciences PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where RPG Life Sciences's PE Ratio without NRI falls into.


NSE:RPGLIFE
92GF Score
RPG Life Sciences Ltd NSE:RPGLIFE
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RPG Life Sciences PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

RPG Life Sciences's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=2440.30/67.959
=35.91

RPG Life Sciences's Share Price of today is ₹2440.30.
RPG Life Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹67.96.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 35.91 mean?
RPG Life Sciences (NSE:RPGLIFE) has a PE Ratio without NRI of 35.91 as of Jul. 07, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on RPG Life Sciences and its competitors. This is 18% above median its historical median of 30.43. Over the past decade, RPG Life Sciences' PE Ratio without NRI has ranged from 9.92 to 145.85. According to the industry distribution chart, RPG Life Sciences ranks #469 out of 654 companies in the Drug Manufacturers industry, placing it in the top 71.7%.
Is RPG Life Sciences' PE Ratio without NRI too high?
RPG Life Sciences' current PE Ratio without NRI of 35.91 is 18% above median its 10-year median of 30.43. Over the past 10 years, this metric has ranged from a low of 9.92 to a high of 145.85. The Drug Manufacturers industry median PE Ratio without NRI is 20.66. RPG Life Sciences' value of 35.91 is 73.8% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #469 out of 654 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' PE Ratio without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #469 out of 654 companies for PE Ratio without NRI. This places RPG Life Sciences in the lower half of its industry. The industry median PE Ratio without NRI is 20.66. RPG Life Sciences' value of 35.91 is 73.8% above this benchmark. Historically, RPG Life Sciences' own PE Ratio without NRI has ranged from 9.92 to 145.85 over the past decade. While the company's 10-year median is 30.43 vs. the industry median of 20.66, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.66, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current PE Ratio without NRI of 35.91 is 73.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on RPG Life Sciences and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current PE Ratio without NRI is 35.91, which is 18% above median its own 10-year median of 30.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,353.66, compared to a current price of ₹2,440.30 — trading 3.7% above its estimated fair value. The current PE Ratio without NRI is 35.91, which is 18% above median its 10-year median of 30.43 and 73.8% above the Drug Manufacturers industry median of 20.66. RPG Life Sciences' overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current PE Ratio without NRI is 35.91 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued. The current stock price of ₹2,440.30 is trading 3.7% above its estimated GF Value™ of ₹2,353.66. GuruFocus considers RPG Life Sciences to be Fairly Valued.

Key valuation signals for NSE:RPGLIFE:

  • PE Ratio without NRI: 35.91 (18% above median its 10-year median of 30.43)
  • GF Value™: ₹2,353.66 vs. price of ₹2,440.30 (3.7% above fair value)
  • GF Score™: 92/100 with 5 warning signs
  • Industry Position: 73.8% above the Drug Manufacturers median (#469 of 654)

No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RPG Life Sciences Business Description

Other Exchanges 532983:India
Address 463, Dr. Annie Besant Road, RPG House, Near Old Passport Office, Worli, Mumbai, MH, IND, 400030
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score

Get the complete analysis for NSE:RPGLIFE

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,440.30
Price
₹2,353.66
GF Value